Asthma exacerbation resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 158: Line 158:


==Don'ts==
==Don'ts==
 
* Don't measure FEV 1 and PEF in a patient presenting with severe [[asthma]] exacerbation and proceed directly to the initiation of the management.
* The following treatments are not recommended during hospitalization or emergency care settings:
* The following treatments are not recommended during hospitalization or emergency care settings:
:* Methylxanthine
:* Methylxanthine

Revision as of 22:35, 15 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Abdurahman Khalil, M.D. [3]

Definition

Asthma exacerbations are acute or subacute episodes of progressively worsening symptoms of cough, wheezing and dyspnea accompanied by a measurable decrease in peak expiratory airflow.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Asthma exacerbation is a life-threatening condition and must be treated as such irrespective of the causes.

Common Causes

  • Occupational irritants and sensitizers

Management

Diagnosis

 
 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
Dyspnea
Wheezing
❑ Chest tightness
Cough
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obtain a focused history:
❑ Onset
❑ Severity compared to previous episodes
❑ Possible causes
❑ Current medications
❑ Time since the last dose of asthma medications
❑ Exacerbations in previous 1 year
❑ Concurrent illness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
Agitation
Tachypnea
Tachycardia
❑ Use of accessory muscles
❑ Speech (full sentences, words)
❑ Level of alertness
❑ Hydration status
❑ Cyanosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order labs:
Spirometry (FEV1, Peak expiratory flow PEF)†
❑ O2 saturation (pulse oximetry)
❑ Arterial blood gas (ABG) (PaO2/PCO2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:
COPD exacerbation
Aspiration pneumonia
Allergy or hay fever
❑ Vocal cord dysfunction
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classify the severity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mild:
Symptoms:
❑ Breathlessness while walking
❑ Speaks full sentences

Signs:
❑ Tachypnea
❑ End expiratory wheezing
❑ Pulse < 100/min


❑ FEV1 ≥ 70%
❑ Pulse oximetry > 95 %

❑ ABG Normal
 
Moderate:
Symptoms:
❑ Breathlessness at rest, prefers sitting
❑ Speaks phrases
❑ Usually agitated

Signs:
❑ Tachypnea
❑ Using accessory muscles of respiration
❑ Expiratory wheezing
❑ Pulse 100-120/min
❑ Pulsus paradoxus may be present


❑ FEV1 40-69 %
❑ Pulse oximetry 90-95 %
❑ ABG:

PaO2 ≥ 60 mm Hg
PCO2 < 42 mm Hg
 
 
 
 
 
Severe:
Symptoms:
❑ Breathlessness at rest, sits upright
❑ Speaks words
❑ Usually agitated

Signs:
❑ Tachypnea ≥ 30/min
❑ Using accessory muscles of respiration
❑ Wheezing throughout inhalation and exhalation
❑ Pulse > 120/min
❑ Pulsus paradoxus present


❑ FEV1 < 40 %
❑ Pulse oximetry < 90 %
❑ ABG:

PaO2 < 60 mm Hg
PCO2 ≥ 42 mm Hg
 
Imminent respiratory arrest:
Symptoms:
❑ Drowsy or confused

Signs:
❑ Paradoxical thoracoabdominal movement
❑ Wheeze absent
❑ Bradycardia
❑ Pulsus paradoxus absent due to resp. fatigue


❑ FEV1 < 25 %
❑ < 10 % in FEV1 after treatment

 
 
 
 
 
 


† In the initial management of severe exacerbations FEV1 and PEF are not included, and the treatment should begin on clinical grounds.

Treatment

 
 
 
 
Mild or moderate exacerbation
FEV1/PEF ≥ 40-60%
 
 
 
 
 
Severe exacerbation
FEV1/PEF ≤ 40%
 
 
Imminent respiratory arrest
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Oxygenate, target SaO2 ≥ 90%
❑ Inhaled SABA by nebulizer or MDI, 3 doses in 1st hour max.
❑ Oral corticosteroid if no response or recent intake of oral steroid
 
 
 
 
 
❑ Oxygenate, target SaO2 ≥ 90%
❑ High dose inhaled SABA/MDI plus ipratropium every 20 mins for 1 hour
❑ oral corticosteroids
 
 
❑ Intubate and mechanically ventilate with 100% O2
❑ Nebulized SABA and ipratropium
❑ IV corticosteroids
❑ Consider adjunct therapies
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reassess for following:
❑ Patients subjective response
❑ Physical findings
❑ FEV1/PEF
❑ Pulse oximetry/ABG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moderate exacerbation:
❑ Inhaled SABA every 60mins
❑ Oral corticosteroid
❑ Treat for 1-3 hours if improvement, admission decision at hours
 
 
 
 
 
Severe exacerbation:
❑ Oxygen
❑ Nebulized SABA + Ipratropium continuous
❑ Oral corticosteroids
❑ consider adjunct therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Good response:
❑ FEV1/PEF > 70%
❑ No distress
❑ Stable after 60 mins of treatment
❑ Normal physical exam
 
Incomplete response:
❑ FEV1/PEF 40-69%
❑ Mild-moderate symptoms
 
Poor response
❑ FEV1/PEF < 40%
❑ PCO2 ≥ 42 mm Hg
❑ Confusion and severe symptoms
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Admit to ward:
❑ Oxygen
❑ Inhaled SABA
❑ Oral or IV corticosteroids
❑ Monitor
 
Admit to ICU:
❑ Oxygen
❑ Inhaled SABA horly or continously
❑ Consider adjunct therapies
❑ Possible intubation and mechanical ventilation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discharge
❑ Continue treatment with inhaled SABA
❑ Continue course of oral steroids
❑ Continue/initiate inhaled corticosteroids
❑ Educate patient
❑ Schedule follow up
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

The following guidelines are based on directives issued by 'National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma'.[6]


Shown below is a table summarizing the dosage of drugs used to manage asthma exacerbation:

DrugAdult dosage
Inhaled Short Acting β Agonists (SABA)
Albuterol/Bitolterol/Pirbuterol
a) Nebulizer solution
b) MDI

♦ 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed or 10-15 mg/hour continuously.
♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed.
Levalbuterol
a) Nebulizer solution
b) MDI

♦ 1.25-2.5 mg every 20 mins for 3 doses, then 1.25-5 mg every 1-4 hours as needed.
♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed.
Anticholinergics
Ipratropium bromide
a) Nebulizer solution
b) MDI

♦ 0.5 mg every 20 mins for 3 doses, then as needed.
♦ 8 puffs every 20 mins as needed for upto 3 hours.
Ipratropium with albuterol
a) Nebulizer solution (each 3 ml containing 0.5 mg ipratropium and 2.5 mg albuterol)
b) MDI (each puff contains 18 mcg ipratropium and 90 mcg albuterol)

♦ 3 ml every 20 mins for 3 doses, then as needed.
♦ 8 puffs every 20 mins as needed for 3 hours
Systemic corticosteroids
Prednisone/Prednisolone/Methylprednisolone ♦ 40-80 mg/day in 1 or 2 divided doses until peak expiratory flowrate (PEF) reaches 70% of personal best.
  • SABA:short acting beta agonist
  • FEV1:forced expiratory volume for the for the first second
  • PEF: Expiratory peak flow

Do's

  • Use the percent predicted FEV1 and peak expiratory flow (PEF) as your main factors to classify the severity of asthma exacerbation.
  • Initiate the treatment of asthma exacerbation as soon as possible while obtaining a brief history and examining the patient.
  • Rule out on physical examination complications of asthma exacerbation sch as pneumonia, pneumomediastinum and pneumothorax.

Ordering labs: These should not hinder administering treatment.

  • Measure serum theophylline concentration in patients who have taken theophylline before presentation.
  • Measure serum electrolytes in patients who have been taking diuretics regularly and in patients who have coexistent cardiovascular disease.
  • Obtain chest radiography for patients suspected of congestive heart failure, or pneumothorax, pneumomediastinum, pneumonia, or lobar atelectasis.
  • Obtain Electrocardiograms in patients older than 50 years of age with evidence of heart disease or COPD.

Drug therapy:

  • Use only selective β agonists to mitigate cardiac risks.
  • Prescribe a 5-10 days course of corticosteroids to prevent early relapse.

Adjunct therapies:

  • Adjunct therapies that may be considered: (Evidence not complete, futhere data is required.)
  • Intravenous magnesium sulfate in patients who have life-threatening exacerbations and in those whose exacerbations remain in the severe category after 1 hour of intensive conventional therapy.
  • Heliox-driven albuterol nebulization for patients who have life-threatening exacerbations and for those patients whose exacerbations remain in the severe category after 1 hour of intensive conventional therapy.
  • Intravenous beta2-agonists
  • Noninvasive ventilation
  • Intravenous leukotriene receptor antagonists

Intubation:

  • Intubate patients presenting with apnea or coma immediately.
  • Should be done by an experienced physician.
  • Use 'Permissive hypercapnia' or 'controlled hypoventilation' as the recommended ventilator strategy.

Discharge:

  • Ensure patient has medication to continue after discharge.
  • Educate patient.
  • Consider issuing a PEF meter.

Don'ts

  • Don't measure FEV 1 and PEF in a patient presenting with severe asthma exacerbation and proceed directly to the initiation of the management.
  • The following treatments are not recommended during hospitalization or emergency care settings:
  • Methylxanthine
  • Antibiotics(except for comorbid conditions)
  • Excessive hydration
  • Mucolytics
  • Chest physical therapy
  • Sedation

References

  1. Adler, VV.; Kiseleva, NP.; Kistanova, EN.; Klenova, EM.; Lobanenkov, VV.; Polotskaia, AV.; Tevosian, SG. "[Differences in expression and functional organization of the rat tyrosine aminotransferase gene in two lines of Morris hepatoma, 8994 and 7777]". Mol Biol (Mosk). 25 (2): 431–41. PMID 1679193.
  2. del Hoyo, N.; Pulido, JA.; Carretero, MT.; Pérez-Albarsanz, MA. (1990). "Comparison of linoleate, palmitate and acetate metabolism in rat ventral prostate". Biosci Rep. 10 (1): 105–12. PMID 2111190. Unknown parameter |month= ignored (help)
  3. Seggev, JS.; Lis, I.; Siman-Tov, R.; Gutman, R.; Abu-Samara, H.; Schey, G.; Naot, Y. (1986). "Mycoplasma pneumoniae is a frequent cause of exacerbation of bronchial asthma in adults". Ann Allergy. 57 (4): 263–5. PMID 3094410. Unknown parameter |month= ignored (help)
  4. Van Winkle, LJ.; Campione, AL.; Gorman, JM.; Weimer, BD. (1990). "Changes in the activities of amino acid transport systems b0,+ and L during development of preimplantation mouse conceptuses". Biochim Biophys Acta. 1021 (1): 77–84. PMID 2104753. Unknown parameter |month= ignored (help)
  5. Ikeda, H.; Mitsuhashi, T.; Kubota, K.; Kuzuya, N.; Uchimura, H. (1985). "Effects of phorbol ester on GH, TSH and PRL release by superfused rat adenohypophysis". Endocrinol Jpn. 32 (5): 759–65. PMID 2868885. Unknown parameter |month= ignored (help)
  6. "Section 5, Managing Exacerbations of Asthma - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf". Retrieved 14 January 2014.